The Immune Correlates of Orthohantavirus Vaccine
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Bae, Joon-Yong | - |
dc.contributor.author | Kim, Jin Il | - |
dc.contributor.author | Park, Mee Sook | - |
dc.contributor.author | Lee, Gee Eun | - |
dc.contributor.author | Park, Heedo | - |
dc.contributor.author | Song, Ki-Joon | - |
dc.contributor.author | Park, Man-Seong | - |
dc.date.accessioned | 2021-11-20T11:40:55Z | - |
dc.date.available | 2021-11-20T11:40:55Z | - |
dc.date.created | 2021-08-30 | - |
dc.date.issued | 2021-05 | - |
dc.identifier.issn | 2076-393X | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/128111 | - |
dc.description.abstract | Zoonotic transmission of orthohantaviruses from rodent reservoirs to humans has been the cause of severe fatalities. Human infections are reported worldwide, but vaccines have been approved only in China and Korea. Orthohantavirus vaccine development has been pursued with no sense of urgency due to the relative paucity of cases in countries outside China and Korea. However, the orthohantaviruses continuously evolve in hosts and thus the current vaccine may not work as well against some variants. Therefore, a more effective vaccine should be prepared against the orthohantaviruses. In this review, we discuss the issues caused by the orthohantavirus vaccine. Given the pros and cons of the orthohantavirus vaccine, we suggest strategies for the development of better vaccines in terms of pandemic preparedness. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | MDPI | - |
dc.title | The Immune Correlates of Orthohantavirus Vaccine | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Jin Il | - |
dc.contributor.affiliatedAuthor | Park, Man-Seong | - |
dc.identifier.doi | 10.3390/vaccines9050518 | - |
dc.identifier.scopusid | 2-s2.0-85106869252 | - |
dc.identifier.wosid | 000654592400001 | - |
dc.identifier.bibliographicCitation | VACCINES, v.9, no.5 | - |
dc.relation.isPartOf | VACCINES | - |
dc.citation.title | VACCINES | - |
dc.citation.volume | 9 | - |
dc.citation.number | 5 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Immunology | - |
dc.relation.journalResearchArea | Research & Experimental Medicine | - |
dc.relation.journalWebOfScienceCategory | Immunology | - |
dc.relation.journalWebOfScienceCategory | Medicine, Research & Experimental | - |
dc.subject.keywordPlus | VIRUS NUCLEOCAPSID PROTEIN | - |
dc.subject.keywordPlus | INACTIVATED HANTAVIRUS VACCINE | - |
dc.subject.keywordPlus | NEUTRALIZING ANTIBODY-RESPONSE | - |
dc.subject.keywordPlus | HEMORRHAGIC-FEVER | - |
dc.subject.keywordPlus | HANTAAN-VIRUS | - |
dc.subject.keywordPlus | RENAL SYNDROME | - |
dc.subject.keywordPlus | SIN-NOMBRE | - |
dc.subject.keywordPlus | ANDES HANTAVIRUS | - |
dc.subject.keywordPlus | PROTECTIVE EFFECTIVENESS | - |
dc.subject.keywordPlus | ETIOLOGIC AGENT | - |
dc.subject.keywordAuthor | antigenicity | - |
dc.subject.keywordAuthor | glycoprotein | - |
dc.subject.keywordAuthor | orthohantavirus | - |
dc.subject.keywordAuthor | pandemic | - |
dc.subject.keywordAuthor | vaccine | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.